Option chain shows key data for ProMIS Neurosciences's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for ProMIS Neurosciences.

ProMIS Neurosciences (NASDAQ:PMN) Stock, Option Chain

ProMIS Neurosciences

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform-ProMIS and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.

Penny,Stock,Investments,Taking,Off,Concept

Penny Stocks

Markets

EMMA

ProMIS Neurosciences And 2 Other Stocks Under $5 Executives Are Buying

Chi sale e chi scende: i maggiori movimenti nel pre-market di oggi

News

Pre-Market Outlook

Movers

Trading Ideas

ALLR

EFSH

FRGT

Maxeon Solar Technologies, Ltd. - Ordinary Shares

MAXN

MYNA

OMEX

PGNY

SGLY

SMSI

TBIO

VEEA

VERO

WBUY

XCUR

Why Exicure Shares Are Trading Higher By Around 180%; Here Are 20 Stocks Moving Premarket

Long Ideas

Insider Trades

PAPL

Around $2M Bet On This Health Care Stock? Check Out These 3 Stocks Under $5 Insiders Are Aggressively Buying

ProMIS Neurosciences Inc. - Common Shares

ProMIS Neurosciences Inc

Perfect Moment Ltd

PERSEUS MINING LTD ORD by Perseus Mining Ltd

Perseus Mining Ltd

Press Releases

ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

ProMIS Neurosciences to Showcase PMN310's Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences

ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer's Disease Conference

ProMIS Neurosciences to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights

ProMIS Neurosciences to Participate in 7th Annual Evercore HealthCONx Conference

ProMIS Neurosciences Initiates Phase 1b Clinical Trial (PRECISE-AD) in Alzheimer's Disease

ProMIS Neurosciences Issues Letter to Shareholders

Biotech

General

ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference

ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer's Disease

BTIG

Comments

ProMIS Neurosciences

ProMIS Neurosciences (PMN) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga